In Depth Research on Global Breast Cancer Predictive Genetic Testing Market Outlook 2022

“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” Report Highlights:

* Hereditary Breast Cancer Genes
* Conceptual of Breast Cancer Susceptibility
* Predictive Cancer Testing Essentials
* Economical, Ethical and Social Aspects
* Global Prevalence of Breast Cancer
* Market and Cost Analysis of Predictive Testing
* Insurance Affairs for Breast Cancer Predictive Testing

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-breast-cancer-predictive-genetic-testing-market-outlook-2022.php

Table of Contents

Cancer Susceptibility Testing
1.1 Prologue to Cancer Susceptibility
1.2 Aspects of Cancer Susceptibility Testing

Breast Cancer Susceptibility
2.1 Conceptual of Breast Cancer Susceptibility
2.2 Trail of the Inherited Susceptible Genes

Hereditary Breast Cancer Genes
3.1 High Penetrant Genes
3.1.1 Breast Cancer Gene1 (BRCA1)
3.1.2 Breast Cancer Gene 2 (BRCA2)
3.1.3 TP53
3.1.4 PTEN
3.1.5 STK11 and CDH1
3.2 Intermediate Penetrant Genes
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
3.2.4 Other Genes
3.3 Low Penetrant Genes

Breast Cancer Susceptible Syndromes
4.1 Hereditary Breast and Ovarian Cancer
4.2 Cowden Syndrome
4.3 Li-Fraumeni Syndrome
4.4 Peutz-Jeghers Syndrome

Cancer Susceptibility Testing Essentials
5.1 Prerequisites towards Cancer Susceptibility
5.2 Sequential Stages in Testing

Genetic Cancer Susceptibility Testing
6.1 Risk Assessment
6.2 Genetic Counseling
6.3 Genetic Testing
6.4 Post-Test Counseling

Management of Hereditary Risk
7.1 Surveillance
7.2 Chemoprevention
7.3 Bilateral Prophylactic Mastectomy

Economical, Ethical and Social Aspects
8.1 Economic Aspects of Cancer Susceptibility Testing
8.2 Ethical Aspects of Cancer Susceptibility Testing
8.3 Social Aspects of Cancer Susceptibility Testing

Global Prevalence of Breast Cancer
9.1 Breast Cancer Incidences
9.2 Germline Breast Cancer Ethnicity

Prevalence over Geographic Regions
10.1 Prevalence in Developed Regions
10.1.1 US
10.1.2 Europe
10.1.3 Canada
10.1.4 Japan
10.2 Prevalence in Developing Regions
10.2.1 China
10.2.2 India
10.2.3 Africa

Preface of Monetary Prospects
11.1 Cost of Breast Cancer Susceptibility Testing
11.2 Insurance Affairs for Breast Cancer Susceptibility Testing

Aspects of Cancer Susceptibility Market
12.1 Breast Cancer Susceptibility Market Overview
12.2 Direct To Consumer Market

Global Breast Cancer Predictive Genetic Testing Market Dynamics
13.1 Accelerative Parameters
13.2 Challenges

Global Breast Cancer Predictive Genetic Testing Market Future Aspects

Competitive Landscape
15.1 Cancer Genetics
15.2 Invitae
15.3 Iverson Genetics
15.4 Myriad Genetics
15.5 NeoGenomics
15.6 Oncocyte
15.7 PerkinElmer
15.8 Quest Diagnostics
15.9 Roche
15.10 Thermo Fisher Scientific

Figure 1-1: Layout of Traditional and Advanced Cancer Susceptibility Testing
Figure 2-1: Demonstration of the Potentials Aspects of the Cancer Susceptibility Testing
Figure 3-1: Common Genetic Variants of Breast Cancer Susceptible Genes
Figure 3-2: Percentage of BRCA1 Gene Mutations and Other Genes for Breast Cancer
Figure 3-3: Breast Cancer Risk by Carriers and Non-Carriers with Growing Age
Figure 3-4: Representation of Gene Specific Lifetime Breast Cancer Risks
Figure 3-5: Percentage of Risk Factors of Breast Cancer and Variability of Penetrance Genes
Figure 4-1: Percentage Share of the Causes of Breast Cancer Risk Assessment
Figure 4-2: Number of Genes Associated With Hereditary Breast Cancer Syndrome
Figure 4-3: The Cumulative Lifetime Risk to Age 70 Years for Breast or Ovarian Cancer
Figure 4-4: Li-Fraumani Syndrome Age Related Risk Patterns for Cancer Development
Figure 5-1: Advantages of Genetic Cancer Susceptibility Tests
Figure 5-2: The Criteria of Target Population for Genetic Testing of Breast Cancer
Figure 5-3: Representation of the Sequential Stages in the Cancer Susceptibility Testing
Figure 6-1: The Concept of Breast Cancer Risk Assessment and Management
Figure 6-2: The Outline of Genetic Test for Breast Cancer Susceptibility
Figure 6-3: Interpretation of Possible Outcomes after Cancer Genetic Testing
Figure 7-1: Management Strategies of Hereditary Risk of Breast Cancer
Figure 7-2: Percentage of Cancer Risk Reductions via Varied Management Strategies
Figure 8-1: Proportion of Cost Effectiveness Ratios in Predictive Genetic Test
Figure 8-2: Ethical Issues of Breast Cancer Susceptibility Testing
Figure 9-1: Global - Demonstration of Incidence and Mortality Rate of Breast Cancer
Figure 9-2: Global - Comparative Percentage of Risk of Developing Breast Cancer in Women
Figure 9-3: US - Prevalence of BRCA Mutation Percentage among White Population
Figure 9-4: UK - Prevalence of BRCA Mutations Percentage among White Population
Figure 9-5: Prevalence of Mutations in Ashkenazi Jewish Individuals
Figure 10-1: US - Rates of Incidence and Mortality Breast Cancer in US as per 100,000
Figure 10-2: US- Prevalence of BRCA1 Mutations Percentage over the Base of Ethnicity
Figure 10-3: Europe - Percentage of Incidence and Mortality of Breast Cancer
Figure 10-4: UK - Rate of Breast Cancer Incidence Related to Age, 2014
Figure 10-5: Europe - Percentage of BRCA1 Mutation in High Risk Families
Figure 10-6: Canada - Percentage of All New Cancer Cases and Breast Cancer Cases, 2016
Figure 10-7: Canada - Percentage of New Breast Cancer Diagnosed in Canadian Women by Age Group, 2016
Figure 10-8: Japan - Incidence Rates of Breast Cancer as per 100,000
Figure 10-9: China - Incidence and Mortality Rates in Chinese Population, 2015
Figure 10-10: India - Percentage of Increasing Incidence of Breast Cancer in Younger Age Groups
Figure 10-11: Central Africa - Age Adjusted Incidence and Death Rates for Breast Cancer
Figure 11-1: US - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-2: UK - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-3: Canada - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-4: Japan - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-5: Australia and New Zealand - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-6: China - Cost of Breast Cancer Susceptibility Testing in China (US$)
Figure 11-7: India - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-8: Singapore - Cost of BRCA Testing and Mastectomy
Figure 12-1: Myriad’s - Market Sales for BRCA Testing (US$ Millions)
Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
Figure 12-3: The Cost Comparison of Myriads BRCA Testing and Other Competitors (US$)
Figure 12-4: Price Difference between Healthcare BRCA Testing and Direct to Consumer Test
Figure 12-5: Global andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-6: US andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-7: Europe andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-8: Asia andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 13-1: Global - Major Parameters of Growth in Breast Cancer Susceptibility Testing
Figure 13-2: Global - Major Challenges of Breast Cancer Susceptibility Market


Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes
Table 7-1: Schedule of Surveillance of Breast Cancer According To Age

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.